A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(6 sites)

United States

Peachford Hospital-Atlanta Behavioral Research, Atlanta, Georgia

University of Cincinnati, Cincinnati, Ohio

Brazil

Instituto Apice, Salvador

Centro Integrado Facili, São Bernardo do Campo

Taiwan

Taipei Veterans General Hospital, Taipei

Tri-Service General Hospital, Taipei